MEK Inhibitor Scores Big Win in Adults, Children With Neurofibromatosis Type 1

(MedPage Today) -- Almost half of adults and children with neurofibromatosis type 1 (NF1) responded to the investigational MEK inhibitor mirdametinib, a large multicenter study of the rare condition showed.
Overall, 53 of 114 patients met response...